Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | RORA | P35398 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | RORB | Q92753 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732980 | 0.91 | AR (0.34) | PDE2AARPDK1PDK2PDK3 | |
| SCHEMBL838873 | 0.90 | PDE2A (0.37) | PDE2AARPDK1PDK2PDK3 | |
| SCHEMBL480547 | 0.88 | HSD11B1 (0.38) | PDE2AARHSD11B1 | |
| SCHEMBL480187 | 0.86 | PDE2A (0.36) | PDE2AESR1ARPDK1PDK2 | |
| SCHEMBL480502 | 0.86 | BRD4 (0.37) | PDE2AARRORARORCRORB | |
| SCHEMBL480497 | 0.85 | ESR1 (0.34) | PDE2AESR1ARPDK1PDK2 | |
| SCHEMBL480047 | 0.84 | AR (0.33) | PDE2AAR | |
| SCHEMBL481100 | 0.84 | MET (0.31) | PDE2A | |
| SCHEMBL735051 | 0.83 | AR (0.30) | AR | |
| SCHEMBL734223 | 0.82 | PDK2 (0.36) | PDE2AARPDK2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | claimed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | claimed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | claimed |
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | disclosed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2411361-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | PDE2A 907/4885ESR1 390/4885AR 187/4885 |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | PDE2A 1196/4885ESR1 236/4885AR 71/4885 |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | PDE2A 1196/4885ESR1 236/4885AR 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.